Over the past twelve years faculty at SUNY-SB and BNL have collaborated to investigate the neurobiology of drug and alcohol abuse, especially the neurobiology of cocaine abuse. These studies at BNL have been supported by both NIDA and NIAAA as well as DOE and have resulted in over 70 publications in this area indexed by MEDLINE. This T32 application will provide postdoctoral training for MDs and PhDs who wish to pursue a career in neuroimaging related to substance abuse. It will focus on aspects of the use of functional brain imaging technology (PET, SPECT, fMRI). For many substance abuse related problems, functional brain imaging technology provides unique research opportunities. Four postdoctoral trainees are currently funded via a similar NIAAA training program to undertake research projects concerned with alcohol. The present (NIDA) application focuses on other drugs of abuse, and in particular on the stimulant drugs cocaine, methamphetamine and tobacco/nicotine. However, every attempt is made to give all our trainees broad exposure in the field of substance and alcohol abuse. Our network of clinical and basic collaborators including individuals such as Dr. Marian Fischman at Columbia University and Dr Alex Makriyannis at the University of Connecticut greatly assists in this effort. Faculty at BNLs have been leaders in the development of radiotracers and methodology for PET, while MRI was developed in the early 70's in the SUNY-SB Chemistry Department. SUNY-SB has a strong presence in the neurosciences, with research conducted within several Departments including Psychiatry, Neurobiology and Behavior, and Psychology. The overall environment at BNL/SUNY-SB provides outstanding opportunities for trainees to develop the skills necessary to pursue careers in brain imaging and drug abuse.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Institutional National Research Service Award (T32)
Project #
1T32DA007316-01A1
Application #
6314456
Study Section
Special Emphasis Panel (ZDA1-RXL-E (07))
Program Officer
Frascella, Joseph
Project Start
2001-07-01
Project End
2006-06-30
Budget Start
2001-07-01
Budget End
2002-06-30
Support Year
1
Fiscal Year
2001
Total Cost
$98,844
Indirect Cost
Name
Brookhaven National Laboratory
Department
Type
DUNS #
027579460
City
Upton
State
NY
Country
United States
Zip Code
11973
Glaser, Sherrye T; Gatley, S John; Gifford, Andrew N (2006) Ex vivo imaging of fatty acid amide hydrolase activity and its inhibition in the mouse brain. J Pharmacol Exp Ther 316:1088-97
Goldstein, Rita Z; Cottone, Lisa A; Jia, Zhiru et al. (2006) The effect of graded monetary reward on cognitive event-related potentials and behavior in young healthy adults. Int J Psychophysiol 62:272-9
Schiffer, W K; Volkow, N D; Fowler, J S et al. (2006) Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse 59:243-51
Chang, L; Cloak, C; Yakupov, R et al. (2006) Combined and independent effects of chronic marijuana use and HIV on brain metabolites. J Neuroimmune Pharmacol 1:65-76
Schiffer, Wynne K; Lee, Dianne E; Alexoff, David L et al. (2006) Metabolic correlates of toluene abuse: decline and recovery of function in adolescent animals. Psychopharmacology (Berl) 186:159-67
Chang, L; Yakupov, R; Cloak, C et al. (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129:1096-112
Chang, Linda; Cloak, Christine; Patterson, Kari et al. (2005) Enlarged striatum in abstinent methamphetamine abusers: a possible compensatory response. Biol Psychiatry 57:967-74
Gatley, S John; Volkow, Nora D; Wang, Gene-Jack et al. (2005) PET imaging in clinical drug abuse research. Curr Pharm Des 11:3203-19
Chang, Sulie L; Cloak, Christine C; Malellari, Lorenc et al. (2005) The effects of repeated endotoxin exposure on rat brain metabolites as measured by ex vivo 1HMRS. J Neuroimmunol 166:39-46
Lindsey, K P; Glaser, S T; Gatley, S J (2005) Imaging of the brain cannabinoid system. Handb Exp Pharmacol :425-43

Showing the most recent 10 out of 12 publications